Co-Diagnostics Shares Plummet Following Dilutive Financing Move

Strategic Developments Amid Financial Turmoil

Co-Diagnostics shares experienced a severe market downturn after the company initiated a substantial equity offering at a deeply discounted price. The financing arrangement, which significantly diluted existing shareholders, triggered an immediate and dramatic selloff that erased more than half of the stock’s value.

Despite the recent market turbulence, Co-Diagnostics continues to advance its operational strategy. The company has established CoMira Diagnostics, a joint venture with Arabian Eagle in Saudi Arabia, designed to expand its footprint across Middle Eastern and North African markets. Clinical testing for tuberculosis, HPV, and respiratory pathogens through this partnership is scheduled to commence before year-end.